Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Quidel Corp receives FDA clearance for its hand-held molecular diagnostic test


Monday, 30 Dec 2013 04:05pm EST 

Quidel Corp:Says it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue Group B Strep Assay.Says AmpliVue is Quidel's non-instrumented molecular diagnostic test that employs a novel amplification technology with an easy-to-use, hand-held device.Says AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification with Quidel's well-established expertise in lateral flow technology to detect Group B Streptococcus from enriched broth cultures of specimens from antepartum women. 

Company Quote

20.7
0.13 +0.63%
4:00pm EDT